JP2013237682A5 - - Google Patents

Download PDF

Info

Publication number
JP2013237682A5
JP2013237682A5 JP2013147411A JP2013147411A JP2013237682A5 JP 2013237682 A5 JP2013237682 A5 JP 2013237682A5 JP 2013147411 A JP2013147411 A JP 2013147411A JP 2013147411 A JP2013147411 A JP 2013147411A JP 2013237682 A5 JP2013237682 A5 JP 2013237682A5
Authority
JP
Japan
Prior art keywords
crystalline form
aripiprazole crystalline
degrees
aripiprazole
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013147411A
Other languages
English (en)
Other versions
JP2013237682A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2013237682A publication Critical patent/JP2013237682A/ja
Publication of JP2013237682A5 publication Critical patent/JP2013237682A5/ja
Pending legal-status Critical Current

Links

Claims (11)

  1. アリピプラゾール結晶質形態IIを調製する方法であって：アリピプラゾール結晶質化合物１を提供し；そしてアリピプラゾール結晶質化合物１を乾燥させてアリピプラゾール結晶質形態IIを調製し、
    前記アリピプラゾール結晶質形態IIが１６．５±０．２、１８．７±０．２、２１．９±０．２、２２．４±０．２及び２３．５±０．２度２θにおけるピークを有するＸＲＤパターンを特徴とし、及び
    前記アリピプラゾール結晶質化合物１が１５．５±０．２、１９．５±０．２、２２．６±０．２、２４．９±０．２及び３０．６±０．２度２θにおけるＸ線粉末回折ピークを有する、方法。
  2. 前記乾燥段階を３５℃の温度で行う、請求項１に記載の方法。
  3. 前記乾燥段階を、１００ｍｍＨｇ以下の圧力で行う、請求項１に記載の方法。
  4. アリピプラゾール結晶質形態II及び医薬的に許容できる賦形剤を含んで成る医薬組成物であって、
    前記アリピプラゾール結晶質形態IIが１６．５±０．２、１８．７±０．２、２１．９±０．２、２２．４±０．２及び２３．５±０．２度２θにおけるピークを有するXRDパターンを特徴とする、医薬組成物。
  5. アリピプラゾール結晶質形態IIと医薬的に許容できる賦形剤を混合することを含んで成る、医薬製剤を調製する方法であって、
    前記アリピプラゾール結晶質形態IIが１６．５±０．２、１８．７±０．２、２１．９±０．２、２２．４±０．２及び２３．５±０．２度２θにおけるピークを有するＸＲＤパターンを特徴とする、方法。
  6. 統合性失調症を治療する医薬組成物であって、統合性失調症に関連する症状を治療、改善、又は軽減するために有効な量においてアリピプラゾール結晶質形態IIを含んで成り、
    前記アリピプラゾール結晶質形態IIが１６．５±０．２、１８．７±０．２、２１．９±０．２、２２．４±０．２及び２３．５±０．２度２θにおけるピークを有するＸＲＤパターンを特徴とする、医薬組成物。
  7. １日あたり０．１ｍｇ／ｋｇ〜１０ｍｇ／ｋｇの体重で投与する、請求項６に記載の医薬組成物。
  8. １ｍｇ〜２００ｍｇ／投与量の量で投与する、請求項７に記載の医薬組成物。
  9. １６．５±０．２、１８．７±０．２、２１．９±０．２、２２．４±０．２及び２３．５±０．２度２θにピークを有するＸＲＤパターンを特徴とする、アリピプラゾール結晶質形態II。
  10. １０．２±０．２、１１．８±０．２、２０．０±０．２、２０．７±０．２、２６．２±０．２、２７．３±０．２及び２９．０±０．２度２θにおけるＸＲＤピークをさらに特徴とする、請求項９に記載のアリピプラゾール結晶質形態II。
  11. １００℃〜１３０℃の範囲に広く且つ小さな吸熱並びに１４８℃〜１５０℃の範囲に融解吸熱を示すＤＳＣをさらに特徴とする、請求項９又は１０に記載のアリピプラゾール結晶質形態II。
JP2013147411A 2003-12-16 2013-07-16 アリピプラゾール結晶質形態を調製する方法 Pending JP2013237682A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US53029703P 2003-12-16 2003-12-16
US60/530,297 2003-12-16
US53383103P 2003-12-30 2003-12-30
US60/533,831 2003-12-30
US61840404P 2004-10-13 2004-10-13
US60/618,404 2004-10-13
US61896004P 2004-10-14 2004-10-14
US60/618,960 2004-10-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006545583A Division JP5546717B2 (ja) 2003-12-16 2004-12-16 アリピプラゾール結晶質形態を調製する方法

Publications (2)

Publication Number Publication Date
JP2013237682A JP2013237682A (ja) 2013-11-28
JP2013237682A5 true JP2013237682A5 (ja) 2014-06-19

Family

ID=34705304

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006545583A Active JP5546717B2 (ja) 2003-12-16 2004-12-16 アリピプラゾール結晶質形態を調製する方法
JP2013147411A Pending JP2013237682A (ja) 2003-12-16 2013-07-16 アリピプラゾール結晶質形態を調製する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006545583A Active JP5546717B2 (ja) 2003-12-16 2004-12-16 アリピプラゾール結晶質形態を調製する方法

Country Status (11)

Country Link
US (2) US7504504B2 (ja)
EP (1) EP1613598B1 (ja)
JP (2) JP5546717B2 (ja)
AT (1) ATE529409T1 (ja)
CA (1) CA2550726A1 (ja)
ES (1) ES2374922T3 (ja)
IL (1) IL175512A (ja)
PL (1) PL1613598T3 (ja)
PT (1) PT1613598E (ja)
TW (1) TW200529850A (ja)
WO (1) WO2005058835A2 (ja)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009990A1 (en) * 2003-07-25 2005-02-03 Hetero Drugs Limited Aripiprazole crystalline forms
US7714129B2 (en) 2003-12-16 2010-05-11 Teva Pharmaceutical Industries Ltd. Methods of preparing anhydrous aripiprazole form II
WO2005094896A2 (en) * 2004-03-26 2005-10-13 Baylor University Targeted serotonin reuptake inhibitors
EP1797039A1 (en) 2004-09-13 2007-06-20 Matrix Laboratories Ltd Process for the preparation of polymorphs, solvates of aripiprazole using aripiprazole acid salts
EP1812397A1 (en) 2004-11-18 2007-08-01 Synthon B.V. Process of making crystalline aripiprazole
CN101087760B (zh) 2004-11-18 2011-09-28 斯索恩有限公司 结晶的阿立哌唑溶剂化物
EP1686117A1 (en) * 2005-01-27 2006-08-02 Sandoz AG Polymorph and solvates of aripiprazole
AU2006224759A1 (en) † 2005-03-17 2006-09-21 Synthon B.V. Process of making crystalline Type II aripiprazole
ES2526415T3 (es) 2005-03-17 2015-01-12 Synthon B.V. Comprimidos farmacéuticos de aripiprazol cristalino de tipo II
CA2605128A1 (en) * 2005-04-15 2007-01-11 Medichem, S.A. Syntheses and preparations of polymorphs of crystalline aripiprazole
MX2007006368A (es) * 2005-09-29 2007-07-11 Teva Pharma Metodos de preparacion de aripiprazol anhidro forma ii.
EP1919453A2 (en) * 2005-12-22 2008-05-14 Teva Pharmaceutical Industries Ltd Processes for reducing particle size of aripiprazole
CA2627695A1 (en) * 2006-01-05 2007-07-19 Teva Pharmaceutical Industries Ltd. Dry formulations of aripiprazole
US8865722B2 (en) 2006-01-05 2014-10-21 Teva Pharmaceutical Industries Ltd. Wet formulations of aripiprazole
TWI394753B (zh) * 2006-03-17 2013-05-01 Otsuka Pharma Co Ltd 新穎替妥牟拉（ｔｅｔｏｍｉｌａｓｔ）晶體
EP1880714A1 (en) 2006-07-20 2008-01-23 Helm AG Amorphous Aripiprazole and Process for the Preparation thereof
US7799790B2 (en) 2006-07-20 2010-09-21 Helm Ag Amorphous aripiprazole and process for the preparation thereof
WO2008020453A2 (en) * 2006-08-17 2008-02-21 Unichem Laboratories Limited A process for the preparation of a novel crystalline polymorph of aripiprazole
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
US8039621B2 (en) 2006-10-24 2011-10-18 Cambrex Charles City, Inc. Process for preparing anhydrous Aripirazole type I
ES2353444T3 (es) 2008-01-23 2011-03-02 Helm Ag Aripiprazol amorfo y procedimiento para su preparación.
EP2238976B1 (en) 2009-04-03 2012-06-27 Hexal AG Oral films comprising 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro- 1H-quinolin-2-one base or salts or hydrates thereof
CN101948426A (zh) * 2010-09-13 2011-01-19 浙江华海药业股份有限公司 一种制备阿立哌唑晶型b的新方法
US9757374B2 (en) 2010-10-28 2017-09-12 Aequus Pharmaceuticals Inc. Aripiprazole compositions and methods for its transdermal delivery
AU2011320758B2 (en) 2010-10-28 2015-09-24 Alpha To Omega Pharmaceutical Consultants, Inc. Aripiprazole compositions and methods for its transdermal delivery
WO2012077134A1 (en) * 2010-12-07 2012-06-14 Ind-Swift Laboratories Limted Process for preparing aripiprazole polymorphs
KR101340214B1 (ko) * 2011-03-31 2013-12-10 주식회사 대웅제약 무수 아리피프라졸 ⅱ형 결정의 제조방법
CN102850268B (zh) * 2011-06-27 2015-07-15 上海中西制药有限公司 阿立哌唑ⅰ型微晶、阿立哌唑固体制剂及制备方法
KR101372840B1 (ko) * 2012-08-02 2014-03-12 주식회사 에스텍파마 무수 아리피프라졸 결정의 제조방법
EP3065700A1 (en) 2013-11-07 2016-09-14 Synthon B.V. Orodispersible pharmaceutical compositions comprising aripiprazole
CR20200220A (es) 2013-11-15 2020-11-18 Akebia Therapeutics Inc FORMAS SÓLIDAS DE ÁCIDO {[5-(3-CLOROFENIL)-3-HIDROXIPIRIDIN-2-CARBONIL]AMINO}ACÉTICO, COMPOSICIONES, Y USOS DE LAS MISMAS (Divisional 2016-0222)
CN106474058B (zh) 2015-08-31 2020-01-07 南京诺瑞特医药科技有限公司 具有延长的保质期的阿立哌唑可注射悬浮液制剂
TWI665194B (zh) * 2016-02-19 2019-07-11 諾瑞特國際藥業股份有限公司 阿立哌唑的新晶型

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130587A (en) * 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JP2608788B2 (ja) 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP3282731B2 (ja) * 1990-06-15 2002-05-20 メルク エンド カムパニー インコーポレーテッド 結晶の構造および大きさを改良する結晶化方法
US6221153B1 (en) * 1998-06-09 2001-04-24 Trevor Percival Castor Method for producing large crystals of complex molecules
IL151838A0 (en) 2000-03-20 2003-04-10 Teva Pharma Processes for preparing 6-hydroxy-3,4-dihydroquinolinone, cilostazol and n- (4-methoxyphenyl)-3-chloropropionamide
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
ITMI20021209A1 (it) 2002-06-04 2003-12-04 Chemi Spa Processo di preparazione di azitromicina ad elevata purezza
RU2342931C2 (ru) * 2002-08-20 2009-01-10 Бристол-Маерс Сквибб Компани Состав на основе комплекса арипипразола
EP1480953B2 (en) * 2003-01-09 2010-08-18 Otsuka Pharmaceutical Co., Ltd. Process for preparing aripiprazole
AU2003230192A1 (en) * 2003-03-21 2004-10-11 Hetero Drugs Limited Novel crystalline forms of aripiprazole
EP1618103A2 (en) * 2003-04-25 2006-01-25 Cadila Healthcare Ltd. Polymorphs of aripiprazole
CA2428237C (en) 2003-05-08 2010-07-20 Delmar Chemicals Inc. Process for the preparation of carbostyril derivatives
WO2005009990A1 (en) 2003-07-25 2005-02-03 Hetero Drugs Limited Aripiprazole crystalline forms
US7166418B2 (en) * 2003-09-03 2007-01-23 Matsushita Electric Industrial Co., Ltd. Sulfonamide compound, polymer compound, resist material and pattern formation method
TWI371274B (en) * 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
US20050277650A1 (en) * 2004-04-20 2005-12-15 Sundaram Venkataraman Process for preparing aripirazole hydrate
US7507823B2 (en) * 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
WO2006012237A2 (en) 2004-06-25 2006-02-02 Shanghai Institute Of Pharmaceutical Industry Aripiprazole crystaline forms and associated methods
EP1797039A1 (en) 2004-09-13 2007-06-20 Matrix Laboratories Ltd Process for the preparation of polymorphs, solvates of aripiprazole using aripiprazole acid salts
US20060079690A1 (en) * 2004-10-12 2006-04-13 Vladimir Naddaka Processes for preparing 7-hydroxy-3,4-dihydro-2(1H)-quinolinone and the use in aripiprazole preparation thereof
US20060079689A1 (en) * 2004-10-12 2006-04-13 Vladimir Naddaka Processes for preparing and purifying carbostyril compounds such as aripiprazole and 7-(4-halobutoxy)-3,4-dihydro-2(1H)-quinolinones
EP1812397A1 (en) * 2004-11-18 2007-08-01 Synthon B.V. Process of making crystalline aripiprazole
CN101087760B (zh) * 2004-11-18 2011-09-28 斯索恩有限公司 结晶的阿立哌唑溶剂化物
EP1686117A1 (en) * 2005-01-27 2006-08-02 Sandoz AG Polymorph and solvates of aripiprazole
JP2009508859A (ja) * 2005-09-15 2009-03-05 エラン ファーマ インターナショナル リミテッド ナノ粒子アリピプラゾール製剤
EP1919453A2 (en) * 2005-12-22 2008-05-14 Teva Pharmaceutical Industries Ltd Processes for reducing particle size of aripiprazole
US20070213535A1 (en) * 2006-03-07 2007-09-13 Chemagis Ltd. Process for the manufacture of aripiprazole by using purified carbostyril compounds such as 7-(4-halobutoxy)-3,4-dihydro-2(1H)-quinolinones
US20060223820A1 (en) * 2006-03-21 2006-10-05 Chemagis Ltd. Crystalline aripiprazole salts and processes for preparation and purification thereof
WO2007113846A1 (en) * 2006-04-03 2007-10-11 Alembic Limited A process for the preparation of aripiprazole
US20070238876A1 (en) * 2006-04-10 2007-10-11 Neera Tewari Process for the preparation of aripiprazole
EP1880714A1 (en) * 2006-07-20 2008-01-23 Helm AG Amorphous Aripiprazole and Process for the Preparation thereof

Similar Documents

Publication Publication Date Title
JP2013237682A5 (ja)
NZ742200A (en) Treatment of osteoarthritis
JP2015193630A5 (ja)
WO2014209841A3 (en) Compounds for treating spinal muscular atrophy
JP2011522827A5 (ja)
JP2014524442A5 (ja)
JP2014527042A5 (ja)
JP2015522037A5 (ja)
JP2013525444A5 (ja)
JP2012176975A5 (ja)
JP2013543867A5 (ja)
JP2014525470A5 (ja)
JP2012516344A5 (ja)
RU2599785C3 (ru) Кристаллические формы 5-хлор-n2-(2-изопропокси-5-метил-4-пиперидин-4-ил-фенил)-n4-[2-(пропан-2-сульфонил)-фенил]-пиримидин-2,4-диамина
JP2015500331A5 (ja)
JP2013507408A5 (ja)
JP2015516425A5 (ja)
JP2016503010A5 (ja)
WO2013188273A8 (en) Topical ophthalmological pharmaceutical composition containing axitinib
WO2013188283A8 (en) Topical ophthalmological pharmaceutical composition containing sunitinib
JP2015537009A5 (ja)
WO2013188268A8 (en) Topical ophthalmological pharmaceutical composition containing pazopanib
JP2013166781A5 (ja)
JP2015516419A5 (ja)
JP2016537326A5 (ja)